Revolution Medicines (RVMD)
155.69
0.00 (0.00%)
Upcoming Events
Latest Headlines
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 3, 2026 8:30 AM - StreetInsider
Revolution (RVMD) PT Raised to $182 at RBC Capital
June 2, 2026 5:03 AM - StreetInsider
Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO
June 2, 2026 4:19 AM - StreetInsider
Revolution (RVMD) PT Raised to $195 at H.C. Wainwright
June 1, 2026 10:45 AM - StreetInsider
TD Cowen Reiterates Buy Rating and Top Pick on Revolution (RVMD)
June 1, 2026 8:28 AM - StreetInsider
Revolution (RVMD) Reiterated at Buy by Stifel
June 1, 2026 7:36 AM - StreetInsider
Revolution (RVMD) PT Raised to $195 at Oppenheimer
June 1, 2026 7:33 AM - StreetInsider
Revolution Medicines reports positive pancreatic cancer trial results
May 31, 2026 8:06 AM - StreetInsider
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic
May 31, 2026 8:06 AM - Globe NewsWire
Form 4 Revolution Medicines, For: May 26 Filed by: Mancini Anthony
May 28, 2026 4:55 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Mancini Anthony
May 26, 2026 4:47 PM - SEC Filing
Bernstein SocGen Group Starts Revolution (RVMD) at Market Perform
May 21, 2026 4:24 PM - StreetInsider
Revolution Medicines schedules call on pancreatic cancer trial results
May 21, 2026 4:13 PM - StreetInsider
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
May 21, 2026 4:05 PM - Globe NewsWire
Truist Securities Assumes Revolution (RVMD) at Buy
May 18, 2026 6:21 AM - StreetInsider
Form SCHEDULE 13G/A Revolution Medicines, Filed by: JANUS HENDERSON GROUP PLC
May 15, 2026 11:24 AM - SEC Filing
Revolution (RVMD) PT Raised to $165 at RBC Capital
May 7, 2026 8:30 AM - StreetInsider
Revolution (RVMD) PT Raised to $172 at Piper Sandler
May 7, 2026 8:06 AM - StreetInsider
Revolution (RVMD) PT Lowered to $183 at Needham
May 7, 2026 7:24 AM - StreetInsider
Revolution (RVMD) PT Raised to $205 at Guggenheim
May 7, 2026 6:39 AM - StreetInsider
Revolution Medicines publishes pancreatic cancer trial data in NEJM
May 6, 2026 6:00 PM - StreetInsider
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 6, 2026 6:00 PM - Globe NewsWire
Form 10-Q Revolution Medicines, For: Mar 31
May 6, 2026 4:12 PM - SEC Filing
Form 8-K Revolution Medicines, For: May 06
May 6, 2026 4:05 PM - SEC Filing
Revolution Medicines, Inc. (RVMD) Misses Q1 EPS by 46c, provides guidance
May 6, 2026 4:05 PM - StreetInsider
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 6, 2026 4:02 PM - Globe NewsWire
Revolution Medicines receives FDA early access authorization for pancreatic cancer pill
May 1, 2026 12:54 PM - StreetInsider
Form 4 Revolution Medicines, For: Apr 27 Filed by: Mancini Anthony
April 29, 2026 5:51 PM - SEC Filing
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
April 29, 2026 4:05 PM - Globe NewsWire
TD Cowen Reiterates Buy Rating on Revolution (RVMD)
April 28, 2026 10:57 AM - StreetInsider
Form DEFA14A Revolution Medicines,
April 28, 2026 6:05 AM - SEC Filing
Form ARS Revolution Medicines, For: Dec 31
April 28, 2026 6:01 AM - SEC Filing
Form DEF 14A Revolution Medicines, For: Jun 18
April 27, 2026 5:31 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Mancini Anthony
April 27, 2026 4:33 PM - SEC Filing
Revolution (RVMD) PT Raised to $185 at Mizuho
April 23, 2026 4:35 AM - StreetInsider
Revolution Medicines presents updated cancer drug trial data at AACR
April 21, 2026 5:35 PM - StreetInsider
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
April 21, 2026 5:35 PM - Globe NewsWire
Revolution Medicines to present new RAS inhibitor data at AACR meeting
April 21, 2026 5:30 PM - StreetInsider
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
April 21, 2026 5:30 PM - Globe NewsWire
Revolution Medicines to present phase 3 pancreatic cancer trial data at ASCO
April 21, 2026 11:23 AM - StreetInsider
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual
April 21, 2026 11:23 AM - Globe NewsWire
Revolution (RVMD) PT Raised to $186 at Needham
April 20, 2026 7:13 AM - StreetInsider
Revolution (RVMD) PT Raised to $215 at Stifel
April 20, 2026 6:03 AM - StreetInsider
Revolution Medicines presents updated zoldonrasib data at AACR meeting
April 19, 2026 2:00 PM - StreetInsider
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
April 19, 2026 2:00 PM - Globe NewsWire
Form 4 Revolution Medicines, For: Apr 15 Filed by: GOLDSMITH MARK A
April 17, 2026 7:26 PM - SEC Filing
Form 8-K Revolution Medicines, For: Apr 14
April 17, 2026 5:17 PM - SEC Filing
Revolution Medicines closes $2.2 billion dual public offerings
April 17, 2026 4:02 PM - StreetInsider
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase
April 17, 2026 4:02 PM - Globe NewsWire
Form 8-K Revolution Medicines, For: Apr 14
April 16, 2026 5:07 PM - SEC Filing
Revolution (RVMD) PT Raised to $175 at JPMorgan
April 16, 2026 8:25 AM - StreetInsider
Form 424B5 Revolution Medicines,
April 15, 2026 5:26 PM - SEC Filing
Form 424B5 Revolution Medicines,
April 15, 2026 5:25 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
April 15, 2026 4:54 PM - SEC Filing
Form 305B2 Revolution Medicines,
April 15, 2026 4:02 PM - SEC Filing
Form FWP Revolution Medicines, Filed by: Revolution Medicines, Inc.
April 15, 2026 6:23 AM - SEC Filing
Revolution Medicines prices $2 billion in upsized stock and bond offerings
April 15, 2026 12:41 AM - StreetInsider
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
April 15, 2026 12:41 AM - Globe NewsWire
Revolution (RVMD) PT Raised to $175 at Guggenheim
April 14, 2026 7:04 AM - StreetInsider
Revolution (RVMD) PT Raised to $167 at Wells Fargo
April 14, 2026 7:01 AM - StreetInsider
Revolution (RVMD) PT Raised to $169 at H.C. Wainwright
April 14, 2026 6:44 AM - StreetInsider
Mizuho Reiterates Outperform Rating on Revolution (RVMD)
April 14, 2026 6:41 AM - StreetInsider
Revolution (RVMD) PT Raised to $162 at RBC Capital
April 14, 2026 6:39 AM - StreetInsider
Revolution (RVMD) PT Raised to $200 at Evercore ISI
April 14, 2026 5:24 AM - StreetInsider
Form 424B5 Revolution Medicines,
April 13, 2026 4:39 PM - SEC Filing
Form 424B5 Revolution Medicines,
April 13, 2026 4:37 PM - SEC Filing
Revolution Medicines announces $1 billion in proposed stock and note offerings
April 13, 2026 4:02 PM - StreetInsider
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
April 13, 2026 4:01 PM - Globe NewsWire
Revolution (RVMD) PT Raised to $165 at Oppenheimer
April 13, 2026 11:28 AM - StreetInsider
Revolution (RVMD) PT Raised to $170 at BofA Securities Amid 36% Gain
April 13, 2026 10:58 AM - StreetInsider
Revolution (RVMD) PT Raised to $147 at Leerink Partners
April 13, 2026 10:37 AM - StreetInsider
Revolution (RVMD) PT Raised to $175 at Raymond James
April 13, 2026 10:24 AM - StreetInsider
Increasing unusual call option volume: ALLO CORN CNK ALMU ADMA JBL SPIR OGN REPL ORBS LWLG CANE RVMD
April 13, 2026 10:16 AM - StreetInsider
Form 8-K Revolution Medicines, For: Apr 13
April 13, 2026 8:25 AM - SEC Filing
Revolution Medicines reports daraxonrasib trial meets survival endpoints
April 13, 2026 8:02 AM - StreetInsider
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
April 13, 2026 8:00 AM - Globe NewsWire
Mizuho Reiterates Outperform Rating on Revolution (RVMD)
April 9, 2026 6:37 AM - StreetInsider
Revolution (RVMD) Reiterated at Buy by Stifel Ahead of Numerous Stock-Moving Events
April 7, 2026 7:52 AM - StreetInsider
Revolution Medicines starts phase 3 trial for pancreatic cancer drug
April 2, 2026 8:01 AM - StreetInsider
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
April 2, 2026 8:01 AM - Globe NewsWire
Form SCHEDULE 13G/A Revolution Medicines, Filed by: VANGUARD GROUP INC
March 27, 2026 11:39 AM - SEC Filing
Form 4 Revolution Medicines, For: Mar 25 Filed by: Mancini Anthony
March 26, 2026 8:04 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Mancini Anthony
March 26, 2026 8:02 PM - SEC Filing
Form 3 Revolution Medicines, For: Mar 20 Filed by: Mancini Anthony
March 26, 2026 6:44 PM - SEC Filing
Form 3 Revolution Medicines, For: Mar 20 Filed by: Sandler Alan B.
March 26, 2026 6:35 PM - SEC Filing
Revolution Medicines (RVMD) call put ratio 1 call to 4.7 puts with a focus on April 70 and 90 puts
March 23, 2026 4:53 AM - StreetInsider
Jefferies says these are the best SMID-cap biotech stocks to buy
March 22, 2026 10:00 AM - StreetInsider
Form 4 Revolution Medicines, For: Mar 17 Filed by: Wei Lin
March 19, 2026 6:58 PM - SEC Filing
Form 4 Revolution Medicines, For: Mar 17 Filed by: Kelsey Stephen Michael
March 19, 2026 6:57 PM - SEC Filing
Form 4 Revolution Medicines, For: Mar 17 Filed by: GOLDSMITH MARK A
March 19, 2026 6:57 PM - SEC Filing
Form 4 Revolution Medicines, For: Mar 17 Filed by: Horn Margaret A
March 19, 2026 6:56 PM - SEC Filing
Form 4 Revolution Medicines, For: Mar 17 Filed by: Anders Jack
March 19, 2026 6:55 PM - SEC Filing
Form 4 Revolution Medicines, For: Mar 17 Filed by: Cislini Jeff
March 19, 2026 6:55 PM - SEC Filing
Form 4 Revolution Medicines, For: Mar 17 Filed by: Wang Xiaolin
March 19, 2026 6:54 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Cislini Jeff
March 19, 2026 4:22 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Anders Jack
March 19, 2026 11:33 AM - SEC Filing
Form 144 Revolution Medicines, Filed by: Cislini Jeff
March 19, 2026 11:33 AM - SEC Filing
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026 6:37 PM - Globe NewsWire
Jefferies Starts Revolution (RVMD) at Buy
March 16, 2026 9:31 AM - StreetInsider
Form 144 Revolution Medicines, Filed by: Wang Xiaolin
March 13, 2026 7:41 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Wei Lin
March 13, 2026 7:40 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Kelsey Stephen Michael
March 13, 2026 7:38 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Horn Margaret A
March 13, 2026 7:36 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
March 13, 2026 7:34 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Cislini Jeff
March 13, 2026 7:32 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Anders Jack
March 13, 2026 7:24 PM - SEC Filing
Full Article List
